Diastolic Cardiac Function Improvement by Liraglutide Is Mainly Body Weight Reduction Dependent but Independently Contributes to B-Type Natriuretic Peptide Reduction in Patients with Type 2 Diabetes with Preserved Ejection Fraction
Table 1
Patient baseline characteristics.
Total ()
With DD ()
Without DD ()
value
Demographics
Male gender (%)
21 (68%)
9 (69%)
12 (67%)
0.88
Age (years)
Diabetes duration (years)
0.59
Body mass index (kg/m2)
0.80
Systolic blood pressure (mmHg)
0.90
Diastolic blood pressure (mmHg)
0.44
Heart rate (bpm)
0.12
B-type natriuretic peptide (pg/mL)
0.62
Blood glucose (mg/dL)
0.099
HbA1c (%)
0.51
Total cholesterol (mg/dL)
0.30
LDL cholesterol (mg/dL)
0.53
HDL cholesterol (mg/dL)
0.56
Triglyceride (mg/dL)
0.32
Creatinine (mg/dL)
0.92
Diabetic complications
Diabetic retinopathy
16 (52%)
8 (62%)
8 (44%)
0.35
Albumin-creatinine rate (mg/g Cr)
0.56
Ischemic heart disease
18 (58%)
9 (69%)
9 (50%)
0.28
Old myocardial infarction
6 (19%)
4 (31%)
2 (11%)
0.17
Cerebrovascular disease
5 (16%)
2 (15%)
3 (17%)
0.92
Medications
Angiotensin II receptor blockers
23 (74%)
11 (85%)
12 (67%)
0.26
Beta-blockers
9 (29%)
4 (31%)
5 (28%)
0.86
Calcium channel blockers
19 (61%)
9 (69%)
10 (56%)
0.44
Loop diuretics
11 (35%)
5 (38%)
6 (33%)
0.77
Statins
22 (71%)
8 (62%)
14 (78%)
0.33
Antiplatelet agents
19 (61%)
8 (62%)
11 (61%)
0.98
Data are or (%) unless otherwise specified. DD: diastolic cardiac dysfunction at baseline; HDL: high-density lipoprotein; LDL: low-density lipoprotein; Cr: creatinine; TTE: transthoracic echocardiography; NA: not applicable. .
